Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

5-year impact of new registered indications on the ESMO-MCBS

Five years of FDA approvals (2017-2022): A report from the ESMO-MCBS


09 Sep 2022


5-year impact of new registered indications on the ESMO-MCBS


Cytotoxic Therapy;  Targeted Therapy;  Cancer Care Equity Principles and Health Economics;  Immunotherapy

Tumour Site


Nathan Cherny


N.I. Cherny

Author affiliations

  • Oncology Institute, Shaare Zedek Medical Center, 9103102 - Jerusalem/IL


Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.